ABSTRACT
Background: Oral cytology studies have claimed that cytoplasmic Periodic Acid Schiff (PAS) positivity in type-2 diabetics is due to glycogen content. But, it can also be due to mucin and glycoconjugates. Aim: 1. To confirm that cytoplasmic PAS positivity in type-2 diabetics is due to glycogen using diastase. 2. To know the effect of diabetes by determining the number of glycogen-containing cells in the smear. 3. To assess the impact of duration of diabetes based on PAS staining of cells. 4. To correlate between random blood glucose level and the number of PAS-positive cells. Materials and Methods: Study population comprised 45 individuals with 30 type-2 diabetics as case group (Group I < 5 years duration; Group II > 5 years duration) and 15 healthy volunteers (age and gender-matched) as control. For all subjects, random blood glucose was estimated and two cytosmears were obtained. The smears were stained with PAS and PAS-diastase stains (PAS-D). Staining intensity was documented as score 1 (mild-to-moderate) and score 2 (moderate-to-intense) and data obtained were statistically analyzed in SPSS version 16.0. Results: Mann-Whitney U test revealed that in diabetics cytoplasmic PAS positivity is because of glycogen (P < 0.05). There is an increase in the number of glycogen-containing cells (P < 0.05) in diabetics. The duration of diabetes had less impact on intracellular glycogen accumulation (P > 0.05). Spearman's correlation test revealed no significant correlation (P > 0.05) between random blood glucose and a number of PAS-positive cells. Conclusion: PAS positivity is because of intracellular glycogen accumulation in type-2 diabetics. It can convey the glycaemic status of an individual in the recent past, thus a beneficial role in screening and therapeutic monitoring.
ABSTRACT
Dyslipidemia is a common complication of renal transplantation referred to as new onset dyslipidemia. Immune suppressants, in particular cyclosporine, the calcineurin inhibitor and others are known to cause dyslipidemia through non-competitive inhibition of sterol 27-dehydroxylase (CYP27A1). On the other hand, dyslipidemia has been found to be associated with higher graft rejection due to decrease in immune suppressant activity and direct graft destruction. Hence the study was designed to analyze the effect of dyslipidemia on chronic allograft rejection. Clinical and biochemistry reports of 142 renal transplant recipients were collected in designed case report forms. All statistical analysis was carried out using International Business Machine (IBM) Statistical Package for Social Sciences (SPSS) 17.0. Immunosuppressive therapy, comorbid diabetes and hypertension, age and serum creatinine were found to be the common predictors of dyslipidemia whereas as dyslipidemia, age and gender were found to be predictors of graft destruction and loss (P>0.05). Incidence of graft loss was found higher in dyslipidemic patients (P<0.05). Dyslipidemia is associated with higher incidence of graft loss and hence renal transplant recipients should be effectively managed with dose intense statin therapy or other safer immunosuppressants. This could increase graft survival rates.